Celanese Corporation
NYSE:CEChemicals
-$0.24 today
- Market cap
- $5.29B
- Beta
- 0.74
- P/E (TTM)
- -5.1
- EPS (TTM)
- -$9.98
- Dividend yield
- 0.24%
Volume 1.38M
Average 2.09M
CE Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Celanese CorporationNYSE: CE
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development declines year over year
Q2 FY2026 research & development of $29M fell 6.5% year over year, behind the -4.0% change in trailing-twelve-month research & development. Sequentially, it rose 3.6% from the prior quarter. Over 3 fiscal years it compounded at +3.7% a year.
Context
- Research & development amounted to 1.3% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -6.5% toward the trailing-twelve-month pace of -4.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 125M USD
- Year-over-year change
- -3.8%
- 4-year CAGR
- +9.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 125M | -3.8% |
| FY2024 | 2024-12-31 | 130M | -11.0% |
| FY2023 | 2023-12-31 | 146M | +30.4% |
| FY2022 | 2022-12-31 | 112M | +30.2% |
| FY2021 | 2021-12-31 | 86M | — |
Research & Development vs competitors
How CE compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -4.0% is the 2nd highest of 5, against a peer median of -10.0%.
- Research & development amounts to 1.2% of revenue for CE, versus a peer median of 0.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2026 | ZAR 474.91M ZAR | — | — | 0.2% | |
| LTM Jun 2026 | $120M USD | -4.0% | +3.7% | 1.2% | |
| LTM Jun 2026 | $55M USD | -9.8% | +2.4% | 1.5% | |
| LTM Jun 2026 | $55M USD | +3.8% | -0.6% | 3.0% | |
| LTM Sep 2026 | $20.81M USD | -10.1% | +14.9% | 1.9% | |
| LTM Jun 2026 | $8.96M USD | — | — | 0.5% | |
| LTM Jun 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Sep 2026 | $0 USD | — | — | 0.0% | |
| LTM Aug 2026 | $0 USD | -100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| Peer median (excluding CE) | — | -10.0% | +2.4% | 0.2% | |
Competitors are the stored peer set for CE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 8.54B | 9.67B | 10.94B | 10.28B | 9.54B |
| Cost of Revenue | 5.86B | 7.29B | 8.34B | 7.92B | 7.75B |
| Gross Profit | 2.68B | 2.38B | 2.6B | 2.36B | 1.79B |
| Gross Margin | 31.4% | 24.6% | 23.8% | 22.9% | 18.8% |
| Research & Development | 86M | 112M | 146M | 130M | 125M |
| Selling, General & Admin | 633M | 824M | 1.08B | 1.03B | 899M |
| Operating Expenses | 736M | 1B | 916M | 3.05B | 1.02B |
| Depreciation & Amortization | 378M | 478M | 711M | 823M | 786M |
| EBITDA | 2.72B | 2.3B | 2.61B | 503M | 335M |
| EBITDA Margin | 31.8% | 23.8% | 23.9% | 4.9% | 3.5% |
| Operating Income | 1.95B | 1.38B | 1.69B | (697M) | 767M |
| Operating Margin | 22.8% | 14.2% | 15.4% | -6.8% | 8.0% |
| Interest Income | 8M | 69M | 39M | 33M | 24M |
| Interest Expense | 100M | 405M | 720M | 676M | 769M |
| Other Income / Expenses | 302M | 43M | (504M) | (299M) | (1.99B) |
| Income Before Tax | 2.25B | 1.42B | 1.18B | (996M) | (1.22B) |
| Pre-Tax Margin | 26.3% | 14.7% | 10.8% | -9.7% | -12.8% |
| Income Tax Expense | 330M | (489M) | (790M) | 510M | (90M) |
| Net Income | 1.89B | 1.89B | 1.96B | (1.52B) | (1.17B) |
| Net Margin | 22.1% | 19.6% | 17.9% | -14.8% | -12.2% |
| EPS (Basic) | 16.99 | 17.48 | 18.01 | (13.93) | (10.64) |
| EPS (Diluted) | 16.86 | 17.34 | 17.92 | (13.93) | (10.64) |
| Weighted Avg Shares | 111.22M | 108.38M | 108.85M | 109.27M | 109.5M |
| Weighted Avg Shares (Diluted) | 112.08M | 109.24M | 109.38M | 109.27M | 109.5M |
Celanese Corporation
NYSE:CE
Intrinsic Alpha fair value
Locked
Current Price
$48.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.